https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-04-01 / Immunol. Rev. 2008 Apr;222:242-55
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-04-01 / Immunol. Rev. 2008 Apr;222:242-552008-04-01 00:00:002019-02-15 09:19:32Cancer vaccines for established cancer: how to make them better?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-04-01 / Immunol. Rev. 2008 Apr;222:28-42
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-04-01 / Immunol. Rev. 2008 Apr;222:28-422008-04-01 00:00:002019-02-15 09:19:33Strategies and challenges in eliciting immunity to melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-04-01 / Int. J. Oncol. 2008 Apr;32(4):777-89
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-04-01 / Int. J. Oncol. 2008 Apr;32(4):777-892008-04-01 00:00:002021-11-15 17:05:15An effective tumor vaccine optimized for costimulation via bispecific and trispecific fusion proteins
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-04-01 / J. Clin. Invest. 2008 Apr;118(4):1427-36
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-04-01 / J. Clin. Invest. 2008 Apr;118(4):1427-362008-04-01 00:00:002008-04-01 00:00:00The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-04-01 / Immunol. Rev. 2008 Apr;222:256-76
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-04-01 / Immunol. Rev. 2008 Apr;222:256-762008-04-01 00:00:002008-04-01 00:00:00Reengineering dendritic cell-based anti-cancer vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-03-28 / Cancer Immunol. Immunother. 2008 Dec;57(12):1745-56
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-03-28 / Cancer Immunol. Immunother. 2008 Dec;57(12):1745-562008-03-28 00:00:002019-02-15 08:59:42Therapeutic efficacy of antitumor dendritic cell vaccinations correlates with persistent Th1 responses, high intratumor CD8+ T cell recruitment and low relative regulatory T cell infiltration
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-03-06 / Leukemia 2008 May;22(5):1007-17
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-03-06 / Leukemia 2008 May;22(5):1007-172008-03-06 00:00:002019-02-15 08:37:27Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+ T cells as well as CD4+CD25+FoxP3+ regulatory T cells toward an antileukemia response
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-03-04 / Radiother Oncol 2008 Mar;86(3):435-42
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-03-04 / Radiother Oncol 2008 Mar;86(3):435-422008-03-04 00:00:002019-02-15 08:59:43Hyperthermia improves the antitumour effect of metronomic cyclophosphamide in a rat transplantable brain tumour
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-03-04 / J. Neuroimmunol. 2008 Mar;195(1-2):21-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-03-04 / J. Neuroimmunol. 2008 Mar;195(1-2):21-72008-03-04 00:00:002019-02-15 09:22:04Brain tumor therapy by combined vaccination and antisense oligonucleotide delivery with nanoparticles
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-03-01 / Bull Cancer 2008 Mar;95(3):320-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-03-01 / Bull Cancer 2008 Mar;95(3):320-62008-03-01 00:00:002019-02-15 08:51:24Immunotherapy of hematological malignancies using dendritic cells
